Avectas is a cell engineering business focused on improving the cost, manufacturing and patient outcomes for the next generation of cellular therapies.
Avectas is developing a novel delivery platform to enable the ex-vivo manufacture of its partners' gene modified cell therapy products, which will retain high in-vivo functionality.
Avectas was founded in 2012 by Shirley O’ Dea and Michael Maguire. The company is headquartered in Maynooth University, Kildare, Ireland, with an office in Cambridge, Massachusetts.
Avectas has developed a unique delivery technology platform, Solupore®, to enable the ex-vivo manufacture of gene modified cell therapy products, with partners. Solupore® is a patented, non-viral, cell engineering technology that permeabilizes the target cell membrane and allows efficient transfer of cargo into cells whilst retaining very high levels of cell viability and functionality.
Avectas' patented Solupore® technology addresses it's academic and commercial partners' need for an efficient, non-viral cell engineering solution. The technology achieves excellent engineering efficiencies for delivery of a broad range of payloads (including mRNA, DNA, proteins and gene editing tools) to primary T cells and NK cells for immuno-oncology and gene editing applications.
Avectas is backed by Seamus Mulligan and others. The company raised $20M in a Series C round on April 16, 2020. This brings Avectas' total funding to oer $40M to date.